NEW YORK – Swiss diagnostics firm ABCDx is developing a point-of-care blood test for stroke to enable faster diagnosis and treatment of the condition.
The Geneva-based company presented data from an ongoing clinical study of the test at the World Stroke Organization Conference (WSOC) held this week in Vienna. In data from 500 patients, the test was able to distinguish between sufferers of ischemic and hemorrhagic stroke with a sensitivity of 50 percent and a specificity of 100 percent.